Pharmaceutical

Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT Preserved Kidney Function Over 12 Months in IgA Nephropathy

Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT Preserved Kidney Function Over 12 Months in IgA Nephropathy

articleOtsuka Holdings Co., Ltd.June 4, 20263/news/otsuka-presents-positive-interim-phase-3-visionary-egfr-data-showing-voyxact-preserved-kidney-function-over-12-months-in-iga-nephropathy
Otsuka Presents Positive Interim Phase 3 VISIONARY eGFR Data Showing VOYXACT Preserved Kidney Function Over 12 Months in IgA Nephropathy

About this update from Otsuka Holdings Co., Ltd.

Otsuka Holdings Co., Ltd. (4578) Press ReleaseView Attachment

View stock analysis, news, and events for Otsuka Holdings Co., Ltd.